GlassScriptPhysician profile
Warren I Okuns
NPI 1134385461
$4,819.04
in general payments reported to CMS, 2019-2025
33 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,150 · 2024: $1,944 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,819.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.86 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.72 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $371.94 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.45 | 2023-2025 | Caplyta |
| Aimmune Therapeutics, INC. | $246.49 | 2024-2025 | Zenpep, Vowst |
| Exact Sciences Corporation | $220.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $203.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $160.92 | 2024-2025 | Camzyos, Cobenfy, Eliquis |
| Pfizer INC. | $157.24 | 2023-2025 | |
| Astellas Pharma US INC | $136.30 | 2024-2025 | Veozah |
| Irhythm Technologies, INC. | $121.10 | 2024 | Zio Monitor, Zio Xt Patch |
| Phathom Pharmaceuticals, INC. | $113.48 | 2024 | Voquezna |
| Abbott Laboratories | $109.13 | 2025 | Freestyle Libre 3, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $98.22 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $97.16 | 2024-2025 | Rexulti, Abilify Maintena |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $77.15 | 2025 | Gemtesa |
| Dexcom, INC. | $73.58 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $56.30 | 2023-2024 | Spravato |
| Viiv Healthcare Company | $40.33 | 2024 | Apretude |
| Corium, LLC | $33.45 | 2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $29.37 | 2025 | |
| Inspire Medical Systems, INC. | $26.46 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $26.39 | 2025 | Shingrix, Arexvy |
| Alkermes, INC. | $26.36 | 2025 | Aristada, Lybalvi |
| Azurity Pharmaceuticals, INC. | $23.64 | 2023 | Horizant |
| Neuronetics, INC. | $21.43 | 2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $18.36 | 2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2025 | Xifaxan |
| Biogen, INC. | $17.42 | 2025 | Zurzuvae |
| Medtronic, INC. | $17.12 | 2023 | Venaseal |
| Vertex Pharmaceuticals Incorporated | $16.08 | 2024 | |
| Exeltis, USA INC. | $13.92 | 2025 | Slynd |
| Bioventus LLC | $12.72 | 2023 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Okuns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.